Kelly C. Goldsmith, MD

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-727-2655
Email Address

kgoldsm@emory.edu

Biography

Kelly Goldsmith, MD, is a professor in the Department of Pediatrics at Emory University School of Medicine. Dr. Goldsmith serves as co-leader of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University, as director Neuroblastoma/MIBG Therapy Program and as clinical director, Aflac Precision Medicine Program at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta. She is board certified in Pediatric Hematology and Oncology by the American Board of Pediatrics, and specializes in the treatment of neuroblastoma, Wilms tumor and other renal tumors of childhood.

Education

Dr. Goldsmith received her Medical Degree from the University of Alabama School of Medicine in Birmingham, Alabama. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at The Children's Hospital of Philadelphia in Philadelphia, Pennsylvania.

Titles & Roles

Curing Kids Cancer Professor of Pediatric Oncology

Emory University School of Medicine
Professor, Department of Pediatrics

Emory University School of Medicine
Co-Leader, Discovery & Developmental Therapeutics Program

Winship Cancer Institute of Emory University
Director Neuroblastoma/MIBG Therapy Program

Aflac Cancer and Blood Disorders Center

Professional Memberships

Dr. Goldsmith holds professional memberships with several scientific societies including American Society of Pediatric Hematology and Oncology, American Association for Cancer Research, American Society of Clinical Oncology, and Children's Oncology Group.

Research

Dr. Goldsmith's laboratory investigates the molecular mechanisms of chemotherapy resistance in pediatric neuroblastoma, focusing on experimental therapeutics that restore therapy sensitivity. Her research expertise is in apoptosis deregulation in cancer, the Bcl-2 family, and neurodevelopmental genes that play a role in therapy resistance. Her translational research provided the concept behind a first in pediatrics Phase I trial of simvastatin in combination with chemotherapy for recurrent solid/CNS tumors of childhood. She is co-chair of a NANT Precision Medicine Study for recurrent neuroblastoma and chair of the AflacST1402 trial. Dr. Goldsmith rounds out her bench to bedside personality as the clinical director of our Refractory and Recurrent Neuroblastoma Program where she and her team work to match a relapsed patient with the appropriate therapy for their recurrent disease.

View Current Clinical Trials


Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma Phase I Conditions Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma Location Winship Cancer Institute
MIBG With Dinutuximab +/- Vorinostat Phase I Conditions Neuroblastoma Location Winship Cancer Institute
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Phase I Conditions Neuroblastoma Location Winship Cancer Institute
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Phase II Conditions Neuroblastoma Location Winship Cancer Institute
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Phase I Conditions Neuroblastoma Location Winship Cancer Institute
Expanded Access Protocol Using 131I-MIBG Phase Expanded Access Conditions Neuroblastoma, Pheochromocytoma, Paraganglioma Location Winship Cancer Institute
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Phase I Conditions Recurrent Neuroblastoma, Refractory Neuroblastoma Location Winship Cancer Institute
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) Phase N/A Conditions Ganglioneuroblastoma, Nodular, Neuroblastoma Location Winship Cancer Institute
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Phase II Conditions High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma Location Winship Cancer Institute

Grants

View Grants

Grant Number	Title
1R01CA248501-01A1	Mechanistic biomarkers to enable Bcl2 inhibitor therapies for neuroblastoma

Publications

Title/Journal	Authors	Publication Date
Trends in analgesia-sedation of pediatric patients receiving I-131 MIBG in the pediatric intensive care unit: A report from the Pediatric Health Information System database. Pediatric blood & cancer	J Dhuse, T Cash, MS Elges, A Alazraki, R Beer, A Jergel, KC Goldsmith, M Hall, PP Kamat	10/01/2024
Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma. Journal of the National Comprehensive Cancer Network : JNCCN	MS Irwin, KC Goldsmith	08/01/2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. Communications biology	K Mittal, GW Cooper, BP Lee, Y Su, KT Skinner, J Shim, HC Jonus, WJ Kim, M Doshi, D Almanza, BD Kynnap, AL Christie, X Yang, GS Cowley, BA Leeper, CL Morton, B Dwivedi, T Lawrence, M Rupji, P Keskula, S Meyer, CM Clinton, M Bhasin, BD Crompton, YY Tseng, JS Boehm, KL Ligon, DE Root, AJ Murphy, DM Weinstock, PC Gokhale, JM Spangle, MN Rivera, EA Mullen, K Stegmaier, KC Goldsmith, WC Hahn, AL Hong	04/08/2024
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. Pediatric blood & cancer	R Bagatell, SG DuBois, A Naranjo, J Belle, KC Goldsmith, JR Park, MS Irwin	09/01/2023
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. Pediatric blood & cancer	T Cash, HC Jonus, M Tsvetkova, JH Beumer, A Sadanand, JY Lee, CJ Henry, D Aguilera, RD Harvey, KC Goldsmith	08/01/2023
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. Cell reports. Medicine	JY Lee, HC Jonus, A Sadanand, GM Branella, V Maximov, S Suttapitugsakul, MJ Schniederjan, J Shim, A Ho, KK Parwani, A Fedanov, AA Pilgrim, JA Silva, RW Schnepp, CB Doering, R Wu, HT Spencer, KC Goldsmith	06/20/2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. Nature communications	ER Berko, GM Witek, S Matkar, ZO Petrova, MA Wu, CM Smith, A Daniels, J Kalna, A Kennedy, I Gostuski, C Casey, K Krytska, M Gerelus, D Pavlick, S Ghazarian, JR Park, A Marachelian, JM Maris, KC Goldsmith, R Radhakrishnan, MA Lemmon, YP Mossé	05/05/2023
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nature medicine	KC Goldsmith, JR Park, K Kayser, J Malvar, YY Chi, SG Groshen, JG Villablanca, K Krytska, LM Lai, PT Acharya, F Goodarzian, B Pawel, H Shimada, S Ghazarian, L States, L Marshall, L Chesler, M Granger, AV Desai, R Mody, DA Morgenstern, S Shusterman, ME Macy, N Pinto, G Schleiermacher, K Vo, HC Thurm, J Chen, M Liyanage, G Peltz, KK Matthay, ER Berko, JM Maris, A Marachelian, YP Mossé	05/01/2023
Identification of a Novel NRG1 Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case Report. Case reports in oncology	SG Mitchell, GD Basu, B Eaton, LJ Goodman, KC Goldsmith	01/01/2023
The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1. Oncoimmunology	AA Pilgrim, HC Jonus, A Ho, AC Cole, J Shim, KC Goldsmith	01/01/2023
A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior. Advanced science (Weinheim, Baden-Wurttemberg, Germany)	L Ning, J Shim, ML Tomov, R Liu, R Mehta, A Mingee, B Hwang, L Jin, A Mantalaris, C Xu, M Mahmoudi, KC Goldsmith, V Serpooshan	08/01/2022
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. The EMBO journal	J Çoku, DM Booth, J Skoda, MC Pedrotty, J Vogel, K Liu, A Vu, EL Carpenter, JC Ye, MA Chen, P Dunbar, E Scadden, TD Yun, E Nakamaru-Ogiso, E Area-Gomez, Y Li, KC Goldsmith, CP Reynolds, G Hajnoczky, MD Hogarty	04/19/2022
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. JCO precision oncology	RJ Summers, SM Castellino, CC Porter, TJ MacDonald, GD Basu, S Szelinger, MK Bhasin, T Cash, AB Carter, RC Castellino, JR Fangusaro, SG Mitchell, MG Pauly, B Pencheva, DS Wechsler, DK Graham, KC Goldsmith	04/01/2022
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials. Oncoimmunology	HC Jonus, RE Burnham, A Ho, AA Pilgrim, J Shim, CB Doering, HT Spencer, KC Goldsmith	01/01/2022
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SG DuBois, MM Granger, S Groshen, D Tsao-Wei, L Ji, A Shamirian, S Czarnecki, F Goodarzian, R Berkovich, H Shimada, JG Villablanca, KT Vo, N Pinto, YP Mosse, JM Maris, S Shusterman, SL Cohn, KC Goldsmith, B Weiss, GA Yanik, CJ Twist, MS Irwin, DA Haas-Kogan, JR Park, A Marachelian, KK Matthay	11/01/2021
A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment. Cancers	J Shim, KC Goldsmith	09/16/2021
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. Molecular cancer therapeutics	L Vernooij, LT Bate-Eya, LK Alles, JY Lee, B Koopmans, HC Jonus, NA Schubert, L Schild, D Lelieveld, DA Egan, M Kerstjens, RW Stam, J Koster, KC Goldsmith, JJ Molenaar, MEM Dolman	06/01/2021
YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma. Cancer research	J Shim, JY Lee, HC Jonus, A Arnold, RW Schnepp, KM Janssen, V Maximov, KC Goldsmith	11/01/2020
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatric blood & cancer	M Qayed, T Cash, M Tighiouart, TJ MacDonald, KC Goldsmith, R Tanos, L Kean, B Watkins, Y Suessmuth, C Wetmore, HM Katzenstein	04/01/2020
Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature. Clinical genitourinary cancer	JT Brown, LR Harik, MS Barbee, N Esiashvili, ML Badell, KC Goldsmith, VA Master, MA Bilen	02/01/2020
Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group. Pediatric blood & cancer	AJ Esbenshade, LS Kahalley, R Baertschiger, R Dasgupta, KC Goldsmith, PC Nathan, P Harker-Murray, CL Kitko, EA Kolb, ES Murphy, JA Muscal, CR Pierson, D Reed, R Schore, Y Unguru, R Venkatramani, B Wistinghausen, G Dhall	10/01/2019
Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. Nature communications	V Maximov, Z Chen, Y Wei, MH Robinson, CJ Herting, NS Shanmugam, VA Rudneva, KC Goldsmith, TJ MacDonald, PA Northcott, D Hambardzumyan, AM Kenney	06/03/2019
Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model. Oncoimmunology	JT Zoine, KA Knight, LC Fleischer, KS Sutton, KC Goldsmith, CB Doering, HT Spencer	01/01/2019
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research	SG DuBois, YP Mosse, E Fox, RA Kudgus, JM Reid, R McGovern, S Groshen, R Bagatell, JM Maris, CJ Twist, K Goldsmith, MM Granger, B Weiss, JR Park, ME Macy, SL Cohn, G Yanik, LM Wagner, R Hawkins, J Courtier, H Lai, F Goodarzian, H Shimada, N Boucher, S Czarnecki, C Luo, D Tsao-Wei, KK Matthay, A Marachelian	12/15/2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. Future oncology (London, England)	AE Place, K Goldsmith, JP Bourquin, ML Loh, L Gore, DA Morgenstern, Y Sanzgiri, D Hoffman, Y Zhou, JA Ross, B Prine, M Shebley, M McNamee, T Farazi, SY Kim, M Verdugo, L Lash-Fleming, CM Zwaan, J Vormoor	09/01/2018
Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction. Transfusion	DV Runco, CD Josephson, SS Raikar, KC Goldsmith, G Lew, M Pauly, RM Fasano	05/01/2018
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research	A Marachelian, JG Villablanca, CW Liu, B Liu, F Goodarzian, HA Lai, H Shimada, HC Tran, JA Parra, R Gallego, N Bedrossian, S Young, S Czarnecki, R Kennedy, BD Weiss, K Goldsmith, M Granger, KK Matthay, S Groshen, S Asgharzadeh, R Sposto, RC Seeger	09/15/2017
Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation. Pediatric blood & cancer	JL Metts, SI Park, BP Soares, C Fong, JA Biegel, KC Goldsmith	09/01/2017
Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement. International journal of radiation oncology, biology, physics	MJ Ferris, H Danish, JM Switchenko, C Deng, BA George, KC Goldsmith, KJ Wasilewski, WT Cash, MK Khan, BR Eaton, N Esiashvili	03/15/2017
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer medicine	C Wetmore, VM Daryani, CA Billups, JM Boyett, S Leary, R Tanos, KC Goldsmith, CF Stewart, SM Blaney, A Gajjar	07/01/2016
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma. BMC cancer	R Tanos, D Karmali, S Nalluri, KC Goldsmith	02/13/2016
EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma. Cancer biology & therapy	S Nalluri, SK Peirce, R Tanos, HA Abdella, D Karmali, MD Hogarty, KC Goldsmith	01/01/2015
Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma. Cell death & disease	TW Laetsch, X Liu, A Vu, M Sliozberg, M Vido, OU Elci, KC Goldsmith, MD Hogarty	02/20/2014
Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer research	KC Goldsmith, M Gross, S Peirce, D Luyindula, X Liu, A Vu, M Sliozberg, R Guo, H Zhao, CP Reynolds, MD Hogarty	05/15/2012